FDA ad­comm votes 8-3 against Cy­to­ki­net­ic­s' po­ten­tial heart fail­ure drug

Af­ter more than a decade and a half in de­vel­op­ment, the FDA’s Car­dio­vas­cu­lar and Re­nal Drugs Ad­vi­so­ry Com­mit­tee to­day vot­ed 8-3 against ap­proval of Cy­to­ki­net­ics’ heart fail­ure drug.

Ad­comm mem­bers said the drug’s po­ten­tial ben­e­fits did not seem to out­weigh its risks, with pan­el mem­bers rais­ing con­cerns about the drug’s safe­ty and its lim­it­ed ef­fi­ca­cy.

The drug, known as ome­cam­tiv mecar­bil (OM), has seen mixed clin­i­cal re­sults, with a first Phase III read­out from No­vem­ber 2020 hit­ting the pri­ma­ry end­point of re­duc­ing the odds of hos­pi­tal­iza­tion or oth­er ur­gent care for heart fail­ure by 8%. But it al­so missed a key sec­ondary end­point an­a­lysts had pegged as key to break­ing in­to the mar­ket.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA